Determination of olanzapine in human plasma and serum by liquid chromatography/tandem mass spectrometry.
A liquid chromatographic/tandem mass spectrometric (LC/MS/MS) assay was developed for the quantitative determination of olanzapine (LY170053, OLZ) in human plasma and serum. Bond Elut C2 solid-phase extraction cartridges (single cartridge or 96-well format), in conjunction with a positive pressure manifold, were used to extract OLZ and its internal standard, LY170222, from the biological matrix. Chromatographic resolution of OLZ from endogenous plasma interferences and its metabolites was accomplished with a MetaChem monochrom HPLC (4.6 x 150 mm, dp 5 microns). Detection was effected with a Perkin-Elmer SCIEX API III Plus mass spectrometer using positive ion atmospheric pressure chemical ionization and a multiple reaction monitoring protocol. The linear dynamic range was from 250 pg ml-1 to 50 ng ml-1 of human plasma/serum using a 0.5 ml aliquot. The inter-day precision (relative standard deviation) and accuracy (relative error) in plasma ranged from 6.26 to 7.66% and from -3.54 to 7.52%, respectively. The intra-day precision and accuracy in serum ranged from 3.46 to 8.76% and from -8.06 to 12.46%, respectively. This assay is sensitive and selective, and will be used to support both human clinical and toxicological analyses. Furthermore, using the 96-well solid-phase extraction format, sample preparation can be easily automated.
Berna
M
M
Department of Drug Disposition, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285, USA. mberna@lilly.com
Shugert
R
R
Mullen
J
J
D014150:Antipsychotic Agents / Q000097:blood*; D001569:Benzodiazepines; D002138:Calibration; D002853:Chromatography, Liquid; D006801:Humans; D013058:Mass Spectrometry; D000077152:Olanzapine; D010890:Pirenzepine / Q000031:analogs & derivatives* / Q000097:blood
D014150:Antipsychotic Agents; D001569:Benzodiazepines; D010890:Pirenzepine; D000077152:Olanzapine